Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 19330009.
- Also identified by DOI 10.1038/nm.1942 and PMC identifier 2904954.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca(2+) release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.
Medical subject headings
- Flecainide
- Tachycardia, Ventricular